Amgen hit with $50.3 mln US verdict in cancer drug patent lawsuit

Reuters12-19 00:30

Amgen hit with $50.3 mln US verdict in cancer drug patent lawsuit

By Blake Brittain

Dec 18 - Amgen's AMGN.O leukemia drug Blincyto infringes patents owned by Germany's Lindis Biotech, a Delaware federal jury said in a verdict made public on Wednesday, awarding Lindis $50.3 million in damages.

The jury said that Amgen infringed two Lindis patents covering immunotherapy innovations. The verdict said Amgen's infringement was willful, which could lead the court to increase the damages award up to $150.9 million.

An Amgen spokesperson said the company was disappointed with the verdict and would seek to overturn it. Attorneys and spokespersons for Lindis did not immediately respond to a request for comment.

Amgen earned $566 million from U.S. sales of Blincyto in 2023, according to a company report.

Lindis sued the Thousand Oaks, California-based Amgen in 2022. It said that Blincyto mimicked Lindis' patented method of using "bispecific" antibodies to stimulate the body's immune system to kill cancer cells.

Amgen denied the allegations and argued that the patents were invalid.

The case is Lindis Biotech GmbH v. Amgen Inc, U.S. District Court for the District of Delaware, No. 1:22-cv-00035.

For Lindis: James Taylor, Jessica Jones, Henry Platt, Robert Gill, Matthew Antonelli, Alireza Behrooz, Dennis Ostrovsky and Courtland Merrill of Saul Ewing

For Amgen: Michael Wise, Joseph Hamilton, Lara Dueppen, Courtney Prochnow and Alisha Burgin of Perkins Coie; Lisa Pensabene, Hassen Sayeed, Carolyn Wall, Luann Simmons and Sorin Zaharia of O'Melveny & Myers

(Reporting by Blake Brittain in Washington)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2492613586?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-19 00:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492613586","market":"us","top_or_hot":-1,"title":"Amgen hit with $50.3 mln US verdict in cancer drug patent lawsuit","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Amgen hit with $50.3 mln US verdict in cancer drug patent lawsuit</title></head><body><p>By Blake Brittain</p><p><span>Dec 18</span><span> - </span>Amgen's <span>AMGN.O</span> leukemia drug Blincyto infringes patents owned by Germany's Lindis Biotech, a Delaware federal jury said in a verdict made public on Wednesday, awarding Lindis $50.3 million in damages.</p><p>The jury said that Amgen infringed two Lindis patents covering immunotherapy innovations. The verdict said Amgen's infringement was willful, which could lead the court to increase the damages award up to $150.9 million.</p><p>An Amgen spokesperson said the company was disappointed with the verdict and would seek to overturn it. Attorneys and spokespersons for Lindis did not immediately respond to a request for comment.</p><p>Amgen earned $566 million from U.S. sales of Blincyto in 2023, according to a company report.</p><p>Lindis sued the Thousand Oaks, California-based Amgen in 2022. It said that Blincyto mimicked Lindis' patented method of using \"bispecific\" antibodies to stimulate the body's immune system to kill cancer cells.</p><p>Amgen denied the allegations and argued that the patents were invalid.</p><p>The case is Lindis Biotech GmbH v. Amgen Inc, U.S. District Court for the District of Delaware, No. 1:22-cv-00035.</p><p>For Lindis: James Taylor, Jessica Jones, Henry Platt, Robert Gill, Matthew Antonelli, Alireza Behrooz, Dennis Ostrovsky and Courtland Merrill of Saul Ewing</p><p>For Amgen: Michael Wise, Joseph Hamilton, Lara Dueppen, Courtney Prochnow and Alisha Burgin of Perkins Coie; Lisa Pensabene, Hassen Sayeed, Carolyn Wall, Luann Simmons and Sorin Zaharia of O'Melveny &amp; Myers</p><p> (Reporting by Blake Brittain in Washington)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amgen hit with $50.3 mln US verdict in cancer drug patent lawsuit</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmgen hit with $50.3 mln US verdict in cancer drug patent lawsuit\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-19 00:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241218:nL6N3NJ0IE:1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Amgen hit with $50.3 mln US verdict in cancer drug patent lawsuitBy Blake BrittainDec 18 - Amgen's AMGN.O leukemia drug Blincyto infringes patents owned by Germany's Lindis Biotech, a Delaware federal...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241218:nL6N3NJ0IE:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4581","symbol_name":"高盛持仓","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241218:nL6N3NJ0IE:1","article_id":"2492613586","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492613586","pubTimestamp":1734539411,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Amgen hit with $50.3 mln US verdict in cancer drug patent lawsuitBy Blake BrittainDec 18 - Amgen's AMGN.O leukemia drug Blincyto infringes patents owned by Germany's Lindis Biotech, a Delaware federal","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4581":"高盛持仓","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","AMGN":"安进","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","BK4599":"减肥药","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","BK4139":"生物科技","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0122379950.USD":"贝莱德世界健康科学A2","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD","BK4566":"资本集团","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4588":"碎股","LU0058720904.USD":"联博国际健康护理基金A","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC"},"translate_title":"安进在抗癌药物专利诉讼中被美国判赔5030万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMGN":0.9},"content_text":"Amgen hit with $50.3 mln US verdict in cancer drug patent lawsuitBy Blake BrittainDec 18 - Amgen's AMGN.O leukemia drug Blincyto infringes patents owned by Germany's Lindis Biotech, a Delaware federal jury said in a verdict made public on Wednesday, awarding Lindis $50.3 million in damages.The jury said that Amgen infringed two Lindis patents covering immunotherapy innovations. The verdict said Amgen's infringement was willful, which could lead the court to increase the damages award up to $150.9 million.An Amgen spokesperson said the company was disappointed with the verdict and would seek to overturn it. Attorneys and spokespersons for Lindis did not immediately respond to a request for comment.Amgen earned $566 million from U.S. sales of Blincyto in 2023, according to a company report.Lindis sued the Thousand Oaks, California-based Amgen in 2022. It said that Blincyto mimicked Lindis' patented method of using \"bispecific\" antibodies to stimulate the body's immune system to kill cancer cells.Amgen denied the allegations and argued that the patents were invalid.The case is Lindis Biotech GmbH v. Amgen Inc, U.S. District Court for the District of Delaware, No. 1:22-cv-00035.For Lindis: James Taylor, Jessica Jones, Henry Platt, Robert Gill, Matthew Antonelli, Alireza Behrooz, Dennis Ostrovsky and Courtland Merrill of Saul EwingFor Amgen: Michael Wise, Joseph Hamilton, Lara Dueppen, Courtney Prochnow and Alisha Burgin of Perkins Coie; Lisa Pensabene, Hassen Sayeed, Carolyn Wall, Luann Simmons and Sorin Zaharia of O'Melveny & Myers (Reporting by Blake Brittain in Washington)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492613586"}